NetworkNewsBreaks – Longeveron Inc.’s (NASDAQ:
Post# of 50
(Total Views: 187)
Posted On: 02/21/2024 2:48:46 PM
NetworkNewsBreaks – Longeveron Inc.’s (NASDAQ: LGVN) ELPIS Trial Demonstrates Potential Survival Benefit of Lomecel-B(TM) for HLHS Patients
Longeveron’s (NASDAQ: LGVN) extended long-term follow-up data from the ELPIS I study was presented as a poster at the annual Scientific Sessions of the American Heart Association (“AHA”). “ELPIS I was designed to assess the safety and potential efficacy of intramyocardial injection of Lomecel-B(TM) administered to 10 infants with hypoplastic left heart syndrome (‘HLHS’) during Stage II surgeries at approximately 4 months of age. The study met the primary safety endpoint: no major adverse cardiac events or any treatment-related infections during the first month post-treatment were reported. Moreover, secondary endpoints measured per protocol suggested Lomecel-B injection may improve patient long-term clinical outcome post-surgery. While the positive results permitted the transition to a Phase II randomized, double-blind, controlled trial, ELPIS II, with enrollment commencing in July 2021, investigators elected to extend follow-up of the 10 infants after ELPIS I came to its planned end for a total period of five years,” a recent article reads. “Long-term follow-up data from our ELPIS I trial demonstrate the continued survival of the participants and reinforce potential survival benefit of Lomecel-B for patients with HLHS,” Joshua M. Hare, Longeveron’s co-founder, chief science officer, and chair of the board of directors, is quoted as saying.
NOTE TO INVESTORS: The latest news and updates relating to LGVN are available in the company’s newsroom at https://nnw.fm/LGVN
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Longeveron’s (NASDAQ: LGVN) extended long-term follow-up data from the ELPIS I study was presented as a poster at the annual Scientific Sessions of the American Heart Association (“AHA”). “ELPIS I was designed to assess the safety and potential efficacy of intramyocardial injection of Lomecel-B(TM) administered to 10 infants with hypoplastic left heart syndrome (‘HLHS’) during Stage II surgeries at approximately 4 months of age. The study met the primary safety endpoint: no major adverse cardiac events or any treatment-related infections during the first month post-treatment were reported. Moreover, secondary endpoints measured per protocol suggested Lomecel-B injection may improve patient long-term clinical outcome post-surgery. While the positive results permitted the transition to a Phase II randomized, double-blind, controlled trial, ELPIS II, with enrollment commencing in July 2021, investigators elected to extend follow-up of the 10 infants after ELPIS I came to its planned end for a total period of five years,” a recent article reads. “Long-term follow-up data from our ELPIS I trial demonstrate the continued survival of the participants and reinforce potential survival benefit of Lomecel-B for patients with HLHS,” Joshua M. Hare, Longeveron’s co-founder, chief science officer, and chair of the board of directors, is quoted as saying.
NOTE TO INVESTORS: The latest news and updates relating to LGVN are available in the company’s newsroom at https://nnw.fm/LGVN
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)